Phosphoinositide signalling in cancer: Beyond PI3K and PTEN

Nature Reviews Cancer

Volumn 10, Issue 5, 2010, Pages 342-352

  Bunney, Tom D ^a   Katan, Matilda ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATASE; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE KINASE; PHOSPHOLIPASE C;

CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL MOTILITY; ENZYME MECHANISM; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 77951568703     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2842     Document Type: Review

References (123)

1. Sasaki, T. et al. Mammalian phosphoinositide kinases and phosphatases. Prog. Lipid Res. 48, 307-343 (2009).
2. Katan, M. New insights into the families of PLC enzymes: looking back and going forward. Biochem. J. 391, e7-e9 (2005).
3. Lemmon, M. A. Phosphoinositide recognition domains. Traffic 4, 201-213 (2003).
4. Lemmon, M. A. Membrane recognition by phospholipid-binding domains. Nature Rev. Mol. Cell Biol. 9, 99-111 (2008).
5. Behnia, R. & Munro, S. Organelle identity and the signposts for membrane traffic. Nature 438, 597-604 (2005).
6. Di Paolo, G. & De Camilli, P. Phosphoinositides in cell regulation and membrane dynamics. Nature 443, 651-657 (2006).
7. Mora, A., Komander, D., van Aalten, D. M. & Alessi, D. R. PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 15, 161-170 (2004).
8. D'Angelo, G., Vicinanza, M., Di Campli, A. & De Matteis, M. A. The multiple roles of PtdIns(4)P\not just the precursor of PtdIns(4, 5)P2. J. Cell Sci. 121, 1955-1963 (2008).
9. Zoncu, R. et al. Loss of endocytic clathrin-coated pits upon acute depletion of phosphatidylinositol 4, 5-bisphosphate. Proc. Natl Acad. Sci. USA 104, 3793-3798 (2007).
10. Yin, H. L. & Janmey, P. A. Phosphoinositide regulation of the actin cytoskeleton. Annu. Rev. Physiol. 65, 761-789 (2003).
11. 2 synthesis in nerve terminals produces defects in synaptic vesicle trafficking. Nature 431, 415-422 (2004).
12. Katso, R. et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17, 615-675 (2001).
13. Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Rev. Genet. 7, 606-619 (2006).
14. Leslie, N. R., Batty, I. H., Maccario, H., Davidson, L. & Downes, C. P. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 27, 5464-5476 (2008).
15. Ooms, L. M. et al. The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease. Biochem. J. 419, 29-49 (2009).
16. Majerus, P. W., Kisseleva, M. V. & Norris, F. A. The role of phosphatases in inositol signaling reactions. J. Biol. Chem. 274, 10669-10672 (1999).
17. Michell, R. H., Heath, V. L., Lemmon, M. A. & Dove, S. K. Phosphatidylinositol 3,5-bisphosphate: metabolism and cellular functions. Trends Biochem. Sci. 31, 52-63 (2006).
18. Clarke, J. H., Richardson, J. P., Hinchliffe, K. A. & Irvine, R. F. Type II PtdInsP kinases: location, regulation and function. Biochem. Soc. Symp. 74, 149-159 (2007).
19. Vicinanza, M., D'Angelo, G., Di Campli, A. & De Matteis, M. A. Phosphoinositides as regulators of membrane trafficking in health and disease. Cell. Mol. Life Sci. 65, 2833-2841 (2008).
20. Krauss, M. & Haucke, V. Phosphoinositide-metabolizing enzymes at the interface between membrane traffic and cell signalling. EMBO Rep. 8, 241-246 (2007).
21. Wymann, M. P. & Schneiter, R. Lipid signalling in disease. Nature Rev. Mol. Cell Biol. 9, 162-176 (2008).
22. Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510 (2008).
23. Liu, P., Cheng, H., Roberts, T. M. & Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Rev. Drug Discov. 8, 627-644 (2009).
24. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Rev. Cancer 9, 550-562 (2009).
25. Ali, I. U., Schriml, L. M. & Dean, M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl Cancer Inst. 91, 1922-1932 (1999).
26. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004). (Pubitemid 38541907)
27. Jaiswal, B. S. et al. Somatic mutations in p85α promote tumorigenesis through class IA PI3K activation. Cancer Cell 16, 463-474 (2009).
28. Samuels, Y. & Velculescu, V. E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3, 1221-1224 (2004).
29. Ikenoue, T. et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65, 4562-4567 (2005).
30. Kang, S., Bader, A. G. & Vogt, P. K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl Acad. Sci. USA 102, 802-807 (2005).
31. Suzuki, A., Nakano, T., Mak, T. W. & Sasaki, T. Portrait of PTEN: messages from mutant mice. Cancer Sci. 99, 209-213 (2008).
32. Chalhoub, N. & Baker, S. J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 4, 127-150 (2009).
33. Maehama, T. PTEN: its deregulation and tumorigenesis. Biol. Pharm. Bull. 30, 1624-1627 (2007).
34. Franke, T. F., Kaplan, D. R., Cantley, L. C. & Toker, A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4- bisphosphate. Science 275, 665-668 (1997).
35. 2 levels determine PKB activity. Cell. Signal. 20, 684-694 (2008).
36. 2 is required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice. J. Biol. Chem. 277, 9027-9035 (2002).
37. Leung, W. H., Tarasenko, T. & Bolland, S. Differential roles for the inositol phosphatase SHIP in the regulation of macrophages and lymphocytes. Immunol. Res. 43, 243-251 (2009).
38. Rohrschneider, L. R., Fuller, J. F., Wolf, I., Liu, Y. & Lucas, D. M. Structure, function, and biology of SHIP proteins. Genes Dev. 14, 505-520 (2000).
39. Helgason, C. D. et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12, 1610-1620 (1998).
40. Sattler, M. et al. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol. Cell. Biol. 19, 7473-7480 (1999).
41. Horn, S. et al. Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3β signaling and leads to an increased transit time through the G1 phase of the cell cycle. Leukemia 18, 1839-1849 (2004).
42. Fukuda, R. et al. Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL). Proc. Natl Acad. Sci. USA 102, 15213-15218 (2005).
43. Ong, C. J. et al. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 11 0, 1942-1949 (2007).
44. Kennah, M. et al. Activation of SHIP via a small molecule agonist kills multiple myeloma cells. Exp. Hematol. 37, 1274-1283 (2009).
45. Garcia-Palma, L. et al. Up-regulation of the T cell quiescence factor KLF2 in a leukaemic T-cell line after expression of the inositol 5'-phosphatase SHIP-1. Br. J. Haematol. 131, 628-631 (2005).
46. Luo, J. M. et al. Mutation analysis of SHIP gene in acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 12, 420-426 (2004).
47. Luo, J. M. et al. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 17, 1-8 (2003).
48. Prasad, N. K., Tandon, M., Badve, S., Snyder, P. W. & Nakshatri, H. Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis 29, 25-34 (2008).
49. Prasad, N. K. SHIP2 phosphoinositol phosphatase positively regulates EGFR-Akt pathway, CXCR4 expression, and cell migration in MDA-MB-231 breast cancer cells. Int. J. Oncol. 34, 97-105 (2009).
50. Sleeman, M. W. et al. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nature Med. 11, 199-205 (2005).
51. Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Rev. Cancer 4, 579-591 (2004).
52. Prasad, N. Tw o diseases with one hit: inhibiting a potential diabetes target to reduce cancer risk and to improve anti-cancer therapy. Curr. Cancer Ther. Rev. 5, 111-121 (2009).
53. Yoon, J. H. et al. cDNA microarray analysis of gene expression profiles associated with cervical cancer. Cancer Res. Treat 35, 451-459 (2003).
54. Chow, K. U. et al. In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling. Pharmacol. Res. 53, 49-61 (2006).
55. Quade, B. J. et al. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosom. Cancer 40, 97-108 (2004).
56. Akada, M. et al. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin. Cancer Res. 11, 3094-3101 (2005).
57. Kim, B. et al. Expression profiling and subtype-specific expression of stomach cancer. Cancer Res. 63, 8248-8255 (2003).
58. Ramaswamy, S., Ross, K. N., Lander, E. S. & Golub, T. R. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49-54 (2003).
59. Gruvberger, S. et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61, 5979-5984 (2001).
60. van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
61. Ooms, L. M. et al. The inositol polyphosphate 5-phosphatase, PIPP, Is a novel regulator of phosphoinositide 3-kinase-dependent neurite elongation. Mol. Biol. Cell 17, 607-622 (2006).
62. Kisseleva, M. V., Cao, L. & Majerus, P. W. Phosphoinositide-specific inositol polyphosphate 5-phosphatase IV inhibits Akt/protein kinase B phosphorylation and leads to apoptotic cell death. J. Biol. Chem. 277, 6266-6272 (2002).
63. Gewinner, C. et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16, 115-125 (2009).
64. Barnache, S., Le Scolan, E., Kosmider, O., Denis, N. & Moreau-Gachelin, F. Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene. Oncogene 25, 1420-1423 (2006).
65. Naylor, T. L. et al. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res. 7, R1186-R1198 (2005).
66. Bergamaschi, A. et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosom. Cancer 45, 1033-1040 (2006).
67. Chin, S. F. et al. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 26, 1959-1970 (2007).
68. Johannsdottir, H. K. et al. Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables. Anticancer Res. 24, 2681-2687 (2004).
69. Ivetac, I. et al. Regulation of PI(3)K/Akt signalling and cellular transformation by inositol polyphosphate 4-phosphatase-1. EMBO Rep. 10, 487-493 (2009).
70. Anderson, R. A., Boronenkov, I. V., Doughman, S. D., Kunz, J. & Loijens, J. C. Phosphatidylinositol phosphate kinases, a multifaceted family of signaling enzymes. J. Biol. Chem. 274, 9907-9910 (1999).
71. Heck, J. N. et al. A conspicuous connection: structure defines function for the phosphatidylinositol-phosphate kinase family. Crit. Rev. Biochem. Mol. Biol. 42, 15-39 (2007).
72. 2 and proteins: interactions, organization, and information flow. Annu. Rev. Biophys Biomol. Struct. 31, 151-175 (2002).
73. 2 synthesis: regulation and cellular functions. J. Cell Sci. 122, 3837-3850 (2009).
74. Mao, Y. S. & Yin, H. L. Regulation of the actin cytoskeleton by phosphatidylinositol 4-phosphate 5 kinases. Pflugers Arch. 455, 5-18 (2007).
75. 2 in cell migration. Trends Cell Biol. 16, 276-284 (2006).
76. Ling, K., Doughman, R. L., Firestone, A. J., Bunce, M. W. & Anderson, R. A. Type I gamma phosphatidylinositol phosphate kinase targets and regulates focal adhesions. Nature 420, 89-93 (2002).
77. Di Paolo, G. et al. Recruitment and regulation of phosphatidylinositol phosphate kinase type 1γ by the FERM domain of talin. Nature 420, 85-89 (2002).
78. Ginsberg, M. H., Partridge, A. & Shattil, S. J. Integrin regulation. Curr. Opin. Cell Biol. 17, 509-516 (2005).
79. Yap, A. S., Crampton, M. S. & Hardin, J. Making and breaking contacts: the cellular biology of cadherin regulation. Curr. Opin. Cell Biol. 19, 508-514 (2007).
80. Collins, B. M., McCoy, A. J., Kent, H. M., Evans, P. R. & Owen, D. J. Molecular architecture and functional model of the endocytic AP2 complex. Cell 109, 523-535 (2002).
81. Ling, K. et al. Type Iγ phosphatidylinositol phosphate kinase modulates adherens junction and E-cadherin trafficking via a direct interaction with μ1B adaptin. J. Cell Biol. 176, 343-353 (2007).
82. Akiyama, C. et al. Phosphatidylinositol-4-phosphate 5-kinase γ is associated with cell-cell junction in A431 epithelial cells. Cell Biol. Int. 29, 514-520 (2005).
83. Wang, Y., Lian, L., Golden, J. A., Morrisey, E. E. & Abrams, C. S. PIP5KIγ is required for cardiovascular and neuronal development. Proc. Natl Acad. Sci. USA 104, 11748-11753 (2007).
84. Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Rev. Cancer 9, 265-273 (2009).
85. Yabuta, T. et al. E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer. Int. J. Cancer 101, 434-441 (2002).
86. Suriano, G. et al. The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell-cell adhesion and to suppress invasion. Oncogene 22, 5716-5719 (2003).
87. Wodarz, A. & Nathke, I. Cell polarity in development and cancer. Nature Cell Biol. 9, 1016-1024 (2007).
88. Katan, M., Rodriguez, R., Matsuda, M., Newbatt, Y. M. & Aherne, G. W. Structural and mechanistic aspects of phospholipase Cγ regulation. Adv. Enzyme Regul. 43, 77-85 (2003).
89. Mouneimne, G. et al. Phospholipase C and cofilin are required for carcinoma cell directionality in response to EGF stimulation. J. Cell Biol. 166, 697-708 (2004).
90. Andrianantoandro, E. & Pollard, T. D. Mechanism of actin filament turnover by severing and nucleation at different concentrations of ADF/cofilin. Mol. Cell 24, 13-23 (2006).
91. Wang, W., Eddy, R. & Condeelis, J. The cofilin pathway in breast cancer invasion and metastasis. Nature Rev. Cancer 7, 429-440 (2007).
92. Song, X. et al. Initiation of cofilin activity in response to EGF is uncoupled from cofilin phosphorylation and dephosphorylation in carcinoma cells. J. Cell Sci. 11 9, 2871-2881 (2006).
93. van Rheenen, J. et al. EGF-induced PIP2 hydrolysis releases and activates cofilin locally in carcinoma cells. J. Cell Biol. 179, 1247-1259 (2007).
94. Frantz, C. et al. Cofilin is a pH sensor for actin free barbed end formation: role of phosphoinositide binding. J. Cell Biol. 183, 865-879 (2008).
95. Leyman, S. et al. Unbalancing the phosphatidylinositol-4, 5-bisphosphate-cofilin interaction impairs cell steering. Mol. Biol. Cell 20, 4509-4523 (2009).
96. Gorbatyuk, V. Y. et al. Mapping the phosphoinositide-binding site on chick cofilin explains how PIP2 regulates the cofilin-actin interaction. Mol. Cell 24, 511-522 (2006).
97. Ghosh, M. et al. Cofilin promotes actin polymerization and defines the direction of cell motility. Science 304, 743-746 (2004).
98. Mouneimne, G. et al. Spatial and temporal control of cofilin activity is required for directional sensing during chemotaxis. Curr. Biol. 16, 2193-2205 (2006).
99. Meira, M. et al. Memo is a cofilin-interacting protein that influences PLCγ1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration. J. Cell Sci. 122, 787-797 (2009).
100. Jones, N. P., Peak, J., Brader, S., Eccles, S. A. & Katan, M. PLCγ1 is essential for early events in integrin signalling required for cell motility. J. Cell Sci. 11 8, 2695-2706 (2005).
101. Jones, N. P. & Katan, M. Role of phospholipase Cγ1 in cell spreading requires association with a beta-Pix/GIT1-containing complex, leading to activation of Cdc42 and Rac1. Mol. Cell. Biol. 27, 5790-5805 (2007).
102. Sun, C. X., Magalhaes, M. A. & Glogauer, M. Rac1 and Rac2 differentially regulate actin free barbed end formation downstream of the fMLP receptor. J. Cell Biol. 179, 239-245 (2007).
103. Noh, D. Y. et al. Elevated content of phospholipase C-γ 1 in colorectal cancer tissues. Cancer 73, 36-41 (1994).
104. Arteaga, C. L. et al. Elevated content of the tyrosine kinase substrate phospholipase C-y 1 in primary human breast carcinomas. Proc. Natl Acad. Sci. USA 88, 10435-10439 (1991).
105. Nomoto, K. et al. Expression of phospholipasesy1, ß 1, and o 1 in primary human colon carcinomas and colon carcinoma cell lines. Mol. Carcinog. 12, 146-152 (1995).
106. Park, J. G. et al. Overexpression of phospholipase C-y 1 in familial adenomatous polyposis. Cancer Res. 54, 2240-2244 (1994).
107. Thomas, S. M. et al. Epidermal growth factor receptor-stimulated activation of phospholipase Cy-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res. 63, 5629-5635 (2003).
108. Shepard, C. R., Kassis, J., Whaley, D. L, Kim, H. G. & Wells, A. PLCy contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 26, 3020-3026 (2007).
109. Sala, G. et al. Phospholipase Cy 1 is required for metastasis development and progression. Cancer Res. 68, 10187-10196 (2008).
110. 2+ entry. Immunity 22, 451-465 (2005).
111. Everett, K. L. et al. Characterization of phospholipase Cy enzymes with gain-of-function mutations. J. Biol. Chem. 284, 23083-23093 (2009).
112. Hynes, N. E. & MacDonald, G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21, 177-184 (2009).
113. Suh, P. G. et al. Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep. 41, 415-434 (2008).
114. Bunney, T. D. & Katan, M. Phospholipase C epsilon: linking second messengers and small GTPases. Trends Cell Biol. 16, 640-648 (2006).
115. Bai, Y. et al. Crucial role of phospholipase Cepsilon in chemical carcinogen-induced skin tumor development. Cancer Res. 64, 8808-8810 (2004).
116. Ikuta, S., Edamatsu, H., Li, M., Hu, L. & Kataoka, T. Crucial role of phospholipase C epsilon in skin inflammation induced by tumor-promoting phorbol ester. Cancer Res. 68, 64-72 (2008).
117. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
118. Min/+ mice through augmentation of inflammation and angiogenesis. Carcinogenesis 30, 1424-1432 (2009).
119. Yuan, T. L. et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc. Natl Acad. Sci. USA 105, 9739-9744 (2008).
120. Xiao, W. et al. Tumor suppression by phospholipase C-ß3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell 16, 161-171 (2009).
121. Van Etten, R. A. & Shannon, K. M. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6, 547-552 (2004).
122. Follo, M. Y et al. Phosphoinositide-phospholipase C ß1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. J. Clin. Oncol. 27, 782-790 (2009).
123. Kolsch, V, Charest, P. G. & Firtel, R. A. The regulation of cell motility and chemotaxis by phospholipid signaling. J. Cell Sci. 121, 551-559 (2008).